Functional	0	10	O
significance	11	23	O
of	24	26	O
VEGF	27	31	B-Gene_or_gene_product
-	31	32	I-Gene_or_gene_product
a	32	33	I-Gene_or_gene_product
in	34	36	O
human	37	42	B-Organism
ovarian	43	50	B-Pathological_formation
carcinoma	51	60	I-Pathological_formation
:	60	61	O
role	62	66	O
in	67	69	O
vasculogenic	70	82	O
mimicry	83	90	O
.	90	91	O

Ovarian	93	100	B-Pathological_formation
cancer	101	107	I-Pathological_formation
is	108	110	O
a	111	112	O
silent	113	119	O
killer	120	126	O
,	126	127	O
and	128	131	O
shows	132	137	O
early	138	143	O
extensive	144	153	O
tumor	154	159	B-Pathological_formation
invasion	160	168	O
and	169	172	O
peritoneal	173	183	B-Multi-tissue_structure
metastasis	184	194	O
.	194	195	O

The	196	199	O
microcirculation	200	216	O
of	217	219	O
most	220	224	O
tumors	225	231	B-Pathological_formation
includes	232	240	O
cooperation	241	252	O
of	253	255	O
pre	256	259	O
-	259	260	O
existing	260	268	O
vessels	269	276	B-Multi-tissue_structure
,	276	277	O
intussusceptive	278	293	O
microvascular	294	307	B-Tissue
growth	308	314	O
,	314	315	O
postnatal	316	325	O
vasculogenesis	326	340	O
,	340	341	O
glomeruloid	342	353	O
angiogenesis	354	366	O
and	367	370	O
vasculogenic	371	383	O
mimicry	384	391	O
(	392	393	O
VM	393	395	O
)	395	396	O
.	396	397	O

VM	398	400	O
is	401	403	O
critical	404	412	O
for	413	416	O
a	417	418	O
tumor	419	424	B-Pathological_formation
blood	425	430	B-Organism_substance
supply	431	437	O
and	438	441	O
is	442	444	O
asscociated	445	456	O
with	457	461	O
aggressive	462	472	O
features	473	481	O
and	482	485	O
metastasis	486	496	O
.	496	497	O

Our	498	501	O
studies	502	509	O
highlight	510	519	O
the	520	523	O
plasticity	524	534	O
of	535	537	O
aggressive	538	548	O
human	549	554	B-Organism
ovarian	555	562	B-Cell
carcinoma	563	572	I-Cell
cells	573	578	I-Cell
and	579	582	O
call	583	587	O
into	588	592	O
question	593	601	O
the	602	605	O
underlying	606	616	O
significance	617	629	O
of	630	632	O
their	633	638	O
ability	639	646	O
to	647	649	O
form	650	654	O
VM	655	657	O
in	658	660	O
vitro	661	666	O
induced	667	674	O
by	675	677	O
VEGF	678	682	B-Gene_or_gene_product
-	682	683	I-Gene_or_gene_product
a	683	684	I-Gene_or_gene_product
.	684	685	O

These	686	691	O
studies	692	699	O
also	700	704	O
show	705	709	O
their	710	715	O
clinicalpathological	716	736	O
features	737	745	O
of	746	748	O
the	749	752	O
cancers	753	760	O
with	761	765	O
human	766	771	B-Organism
Paraffin	772	780	O
-	780	781	O
embedded	781	789	O
tumor	790	795	B-Tissue
tissue	796	802	I-Tissue
samples	803	810	I-Tissue
.	810	811	O

Results	812	819	O
show	820	824	O
that	825	829	O
the	830	833	O
process	834	841	O
:	841	842	O
VEGF	843	847	B-Gene_or_gene_product
-	847	848	I-Gene_or_gene_product
a	848	849	I-Gene_or_gene_product
-	849	850	O
-	850	851	O
greater	852	859	O
than	860	864	O
EphA2	865	870	B-Gene_or_gene_product
-	870	871	O
-	871	872	O
greater	873	880	O
than	881	885	O
MMPs	886	890	B-Gene_or_gene_product
-	890	891	O
-	891	892	O
greater	893	900	O
than	901	905	O
VM	906	908	O
is	909	911	O
the	912	915	O
main	916	920	O
pathway	921	928	O
for	929	932	O
VM	933	935	O
formation	936	945	O
and	946	949	O
VEGF	950	954	B-Gene_or_gene_product
-	954	955	I-Gene_or_gene_product
a	955	956	I-Gene_or_gene_product
appears	957	964	O
to	965	967	O
play	968	972	O
an	973	975	O
important	976	985	O
role	986	990	O
in	991	993	O
the	994	997	O
formation	998	1007	O
of	1008	1010	O
VM	1011	1013	O
based	1014	1019	O
on	1020	1022	O
our	1023	1026	O
in	1027	1029	O
vitro	1030	1035	O
assays	1036	1042	O
and	1043	1046	O
clinical	1047	1055	O
immunohistochemical	1056	1075	O
analyses	1076	1084	O
.	1084	1085	O

VM	1086	1088	O
-	1088	1089	O
targeting	1089	1098	O
strategies	1099	1109	O
for	1110	1113	O
ovarian	1114	1121	B-Pathological_formation
cancer	1122	1128	I-Pathological_formation
include	1129	1136	O
anti	1137	1141	O
-	1141	1142	O
VEGF	1142	1146	B-Gene_or_gene_product
-	1146	1147	I-Gene_or_gene_product
a	1147	1148	I-Gene_or_gene_product
treatment	1149	1158	O
,	1158	1159	O
knocking	1160	1168	O
down	1169	1173	O
the	1174	1177	O
EphA2	1178	1183	B-Gene_or_gene_product
gene	1184	1188	O
and	1189	1192	O
using	1193	1198	O
antibodies	1199	1209	O
against	1210	1217	O
human	1218	1223	B-Organism
MMPs	1224	1228	B-Gene_or_gene_product
if	1229	1231	O
the	1232	1235	O
tumor	1236	1241	B-Pathological_formation
is	1242	1244	O
VM	1245	1247	O
positive	1248	1256	O
.	1256	1257	O

This	1258	1262	O
strategy	1263	1271	O
may	1272	1275	O
be	1276	1278	O
of	1279	1281	O
significant	1282	1293	O
value	1294	1299	O
in	1300	1302	O
laying	1303	1309	O
the	1310	1313	O
foundation	1314	1324	O
for	1325	1328	O
a	1329	1330	O
more	1331	1335	O
explicit	1336	1344	O
anti	1345	1349	O
-	1349	1350	O
tumor	1350	1355	B-Pathological_formation
angiogenesis	1356	1368	O
therapy	1369	1376	O
.	1376	1377	O

